30,000 volunteers - and counting!

Posted:
17
September 2004

Today we are celebrating after successfully recruiting our 30,000th clinical trial volunteer. This major milestone has been reached in just two and a half years, demonstrating that we continue to lead the market in volunteer recruitment.Wendy Galloway, head of Volunteer Recruitment, commented: “We are all delighted to have recruited 30,000 volunteers in such a short period of time, and I would like to thank everyone within our dedicated volunteer recruitment team for making this possible. I would also like to thank the hundreds of volunteers who participate in our trials every month — we appreciate that their full co-operation is pivotal to any study, which is why we make the time they spend staying in our wards as safe, comfortable and enjoyable as possible.”Our highly motivated volunteer recruitment team consistently recruits over 1,000 volunteers a month. We have an integrated sales and marketing approach to recruitment, including targeted advertising campaigns and our dedicated recruitment website www.trials4us.co.uk.Due to the increasing number of studies conducted by Richmond, the volunteer recruitment team is constantly building upon our impressive volunteer database to ensure that all study recruitment targets are met. The database encompasses a wide range of populations, for instance 14% of the database are healthy volunteers aged 60 years or above. We guarantee volunteer panels for all our clients. For more information visit our volunteer recruitment section.

Trials4us

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more